Back to top
more

Zevra Therapeutics, Inc. (ZVRA)

(Delayed Data from NSDQ)

$4.60 USD

4.60
271,570

+0.04 (0.77%)

Updated May 29, 2024 03:59 PM ET

After-Market: $4.59 -0.01 (-0.11%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth A Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (85 out of 249)

Industry: Medical - Drugs

Better trading starts here.

Zacks News

Zevra Therapeutics (ZVRA) Reports Q1 Loss, Lags Revenue Estimates

Zevra Therapeutics (ZVRA) delivered earnings and revenue surprises of 18.37% and 2.70%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Esperion Therapeutics (ESPR) Q1 Earnings and Revenues Beat Estimates

Esperion Therapeutics (ESPR) delivered earnings and revenue surprises of 525% and 159.32%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Will OptiNose (OPTN) Report Negative Q1 Earnings? What You Should Know

OptiNose (OPTN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will Zevra Therapeutics (ZVRA) Report Negative Earnings Next Week? What You Should Know

Zevra Therapeutics, Inc. (ZVRA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Alpine Immune Sciences, Inc. (ALPN) Q4 Earnings and Revenues Beat Estimates

Alpine Immune Sciences, Inc. (ALPN) delivered earnings and revenue surprises of 146.88% and 346.89%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Zevra Therapeutics (ZVRA) Soars 6.6%: Is Further Upside Left in the Stock?

Zevra Therapeutics (ZVRA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Strength Seen in Silence Therapeutics PLC Sponsored ADR (SLN): Can Its 15.4% Jump Turn into More Strength?

Silence Therapeutics PLC Sponsored ADR (SLN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

How Much Upside is Left in Zevra Therapeutics (ZVRA)? Wall Street Analysts Think 248.51%

The consensus price target hints at a 248.5% upside potential for Zevra Therapeutics (ZVRA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Acer (ACER) to Get Acquired by Zevra for $91M, Stock Up

Acer (ACER) surges as Zevra Therapeutics offers to acquire it for approximately $91 million.

Can Zevra Therapeutics (ZVRA) Climb 227.55% to Reach the Level Wall Street Analysts Expect?

The mean of analysts' price targets for Zevra Therapeutics (ZVRA) points to a 227.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Sol-Gel Technologies Ltd. (SLGL) Reports Q2 Loss, Lags Revenue Estimates

Sol-Gel Technologies Ltd. (SLGL) delivered earnings and revenue surprises of 15.38% and 61.68%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Catalyst Pharmaceutical (CPRX) Beats Q2 Earnings and Revenue Estimates

Catalyst (CPRX) delivered earnings and revenue surprises of 32% and 7.35%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

FibroGen (FGEN) Reports Q2 Loss, Tops Revenue Estimates

FibroGen (FGEN) delivered earnings and revenue surprises of 9.72% and 29.72%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Zevra Therapeutics (ZVRA) Reports Q1 Loss, Tops Revenue Estimates

Zevra Therapeutics (ZVRA) delivered earnings and revenue surprises of -30.77% and 3.94%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

OptiNose (OPTN) Reports Q1 Loss, Tops Revenue Estimates

OptiNose (OPTN) delivered earnings and revenue surprises of -6.25% and 15.01%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Cronos Group (CRON) Reports Q1 Loss, Lags Revenue Estimates

Cronos (CRON) delivered earnings and revenue surprises of 25% and 13.42%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?